AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30871907 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined, but implied as the comparison between techniques)
Number of subjects: 60
Study 27930762 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-fractionation RT (70 Gy/35 over 7 weeks) plus cisplatin at 100 mg/m2 intravenous for 3 doses (arm A)
Number of subjects: 320
Study 27930762 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated-fractionation RT (70 Gy/35 over 6 weeks) plus panitumumab at 9 mg/kg intravenous for 3 doses (arm B)
Number of subjects: 320
Study 27930762 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-fractionation RT plus cisplatin (arm A)
Number of subjects: 320
Study 27930762 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated-fractionation RT plus panitumumab (arm B)
Number of subjects: 320
Study 26446978 — intervention group
Group type: EXPERIMENTAL
Intervention: RSA-BF training (5 weekly 45 min sessions)
Number of subjects: 31
Study 26446978 — intervention group
Group type: COMPARATOR
Intervention: Control group (daily stress diary once a week)
Number of subjects: 31
Study 25123549 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg ASA daily
Number of subjects: 186
Study 21740452 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard triple therapy plus vitamins C and E (lansoprazole 30 mg BID, amoxicillin 1000 mg BID, clarithromycin 500 mg BID for 14 days, plus vitamin C 500 mg BID and vitamin E 200 IU BID for 30 days)
Number of subjects: 200
Study 21740452 — intervention group
Group type: COMPARATOR
Intervention: Standard triple therapy (lansoprazole 30 mg BID, amoxicillin 1000 mg BID, clarithromycin 500 mg BID for 14 days)
Number of subjects: 200
Study 19710219 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound guidance
Number of subjects: 40
Study 19710219 — intervention group
Group type: COMPARATOR
Intervention: Electrical stimulation (ES)
Number of subjects: 40
Study 17259945 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (45 mg/day for 4 months)
Number of subjects: 27
Study 17259945 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 15836567 — intervention group
Group type: EXPERIMENTAL
Intervention: BoNT‐A
Number of subjects: 228
Study 15836567 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 228
Study 11994827 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal Therapeutic System (TTS) fentanyl with intramuscular Demerol
Number of subjects: 32
Study 11994827 — intervention group
Group type: COMPARATOR
Intervention: Placebo system with intramuscular Demerol
Number of subjects: 32
Study 9665006 — intervention group
Group type: EXPERIMENTAL
Intervention: CsA + Aza
Number of subjects: 83
Study 9665006 — intervention group
Group type: COMPARATOR
Intervention: CsA + Pred
Number of subjects: 83
Study 7516014 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril (4 mg, single morning dose for 6 weeks)
Number of subjects: 51
Study 7516014 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 7516014 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril
Number of subjects: 51
Study 2465647 — intervention group
Group type: EXPERIMENTAL
Intervention: Irradiation + Surgery (Group 1 - 97 cases)
Number of subjects: 208
Study 2465647 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone (Group 2 - 111 cases)
Number of subjects: 208
Study 4911757 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinidine bisulphate 1.5 g per day in two 12-hourly doses
Number of subjects: 92
Study 4911757 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 31969264 — intervention group
Group type: COMPARATOR
Intervention: tDCS
Number of subjects: 243
Study 31969264 — intervention group
Group type: COMPARATOR
Intervention: escitalopram
Number of subjects: 243
Study 31969264 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 243
Study 31969264 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS vs. escitalopram
Number of subjects: 243
Study 31184266 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy (listening to music through binaural headphones during pre-, intra-, and postprocedural periods)
Number of subjects: 0
Study 31184266 — intervention group
Group type: COMPARATOR
Intervention: Control group (no music therapy)
Number of subjects: 0
Study 28542581 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimanual condition with a ratio of 4:3 (4 taps against 3 sawing cycles per measure)
Number of subjects: 0
Study 28542581 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimanual condition with a ratio of 3:4 (3 taps against 4 sawing cycles per measure)
Number of subjects: 0
Study 28542581 — intervention group
Group type: COMPARATOR
Intervention: Single handed tapping and sawing
Number of subjects: 0
Study 28542581 — intervention group
Group type: EXPERIMENTAL
Intervention: Free tapping
Number of subjects: 0
Study 25919976 — intervention group
Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal conjugate vaccine (PCV13)
Number of subjects: 178
Study 25919976 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 178
Study 25919976 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (IBD patients on no immunosuppressive therapy)
Number of subjects: 178
Study 25919976 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (IBD patients on tumor necrosis factor agents or immunomodulators)
Number of subjects: 178
Study 23918750 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-(1-7) infusion (3 incremental doses: 0.27, 0.9, and 2.7 ng/kg per minute)
Number of subjects: 57
Study 23918750 — intervention group
Group type: COMPARATOR
Intervention: Angiotensin-(1-7) infusion with low sodium intake and/or angiotensin II co-infusion (0.3 ng/kg per minute)
Number of subjects: 57
Study 23918750 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-(1-7) infusion
Number of subjects: 57
Study 22164500 — intervention group
Group type: EXPERIMENTAL
Intervention: Jian-gan-le
Number of subjects: 80
Study 22164500 — intervention group
Group type: COMPARATOR
Intervention: Compound purple granules (Control)
Number of subjects: 80
Study 19329178 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxin 30 microg/kg per day
Number of subjects: 234
Study 19329178 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxin (all doses)
Number of subjects: 234
Study 19329178 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 234
Study 17082899 — intervention group
Group type: EXPERIMENTAL
Intervention: Subunit virus vaccine adjuvanted with MF59
Number of subjects: 0
Study 17082899 — intervention group
Group type: COMPARATOR
Intervention: Split virus vaccine
Number of subjects: 0
Study 15023372 — intervention group
Group type: EXPERIMENTAL
Intervention: Varied post-natal lying positions (back, prone, and side) using a specially designed moldable mattress
Number of subjects: 60
Study 15023372 — intervention group
Group type: COMPARATOR
Intervention: Standard lying position (stomach) with standard orthopaedic bolster support under hips
Number of subjects: 60
Study 15383481 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term oral anticoagulant (OAC) therapy (target INR 2.5; range 2.0 to 3.0) for patients with rheumatic mitral valve disease and AF or history of systemic embolism.
Number of subjects: 0
Study 15383481 — intervention group
Group type: EXPERIMENTAL
Intervention: Adding aspirin, 75 to 100 mg/d for patients with rheumatic mitral valve disease with AF or history of systemic embolism who suffer systemic embolism while receiving OACs at a therapeutic INR.
Number of subjects: 0
Study 15383481 — intervention group
Group type: EXPERIMENTAL
Intervention: Adding dipyridamole, 400 mg/d, or clopidogrel for patients unable to take aspirin.
Number of subjects: 0
Study 15383481 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term aspirin therapy, 50 to 162 mg/d for patients with MVP and documented but unexplained TIAs.
Number of subjects: 0
Study 15383481 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K antagonists for all patients with mechanical prosthetic heart valves.
Number of subjects: 0
Study 15383481 — intervention group
Group type: EXPERIMENTAL
Intervention: Target INR of 2.5 (range 2.0 to 3.0) for patients with St. Jude Medical bileaflet valve in the aortic position.
Number of subjects: 0
Study 15383481 — intervention group
Group type: EXPERIMENTAL
Intervention: Target INR of 3.0 (range 2.5 to 3.5) for patients with tilting disk valves and bileaflet mechanical valves in the mitral position.
Number of subjects: 0
Study 15383481 — intervention group
Group type: EXPERIMENTAL
Intervention: Target INR of 3.0 (range 2.5 to 3.5) in combination with aspirin, 75 to 100 mg/d for patients with caged ball or caged disk valves.
Number of subjects: 0
Study 15383481 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K antagonists with a target INR of 2.5 (range 2.0 to 3.0) for the first 3 months after valve insertion in the mitral position for patients with bioprosthetic valves.
Number of subjects: 0
Study 15383481 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term (> 3 months) therapy with aspirin, 75 to 100 mg/d for patients with bioprosthetic valves who are in sinus rhythm and do not have AF.
Number of subjects: 0
Study 15383481 — intervention group
Group type: EXPERIMENTAL
Intervention: No antithrombotic therapy for patients with MVP without history of systemic embolism, unexplained TIAs, or AF.
Number of subjects: 0
Study 10522839 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin plus repaglinide (MET/REP)
Number of subjects: 83
Study 10522839 — intervention group
Group type: COMPARATOR
Intervention: Metformin plus placebo (MET)
Number of subjects: 83
Study 10522839 — intervention group
Group type: COMPARATOR
Intervention: Repaglinide plus placebo (REP)
Number of subjects: 83
Study 7760966 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin monotherapy (20 to 80 mg/day)
Number of subjects: 44
Study 7760966 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin in combination with other lipid-lowering agents
Number of subjects: 44
Study 7760966 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (both monotherapy and combination therapy)
Number of subjects: 44
Study 7760966 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 44
Study 2184703 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalbuphine
Number of subjects: 60
Study 2184703 — intervention group
Group type: COMPARATOR
Intervention: Nefopam
Number of subjects: 60
Study 452619 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicomorphine diluted with water
Number of subjects: 120
Study 452619 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicomorphine diluted with propylenglykol
Number of subjects: 120
Study 452619 — intervention group
Group type: COMPARATOR
Intervention: Propylenglykol alone
Number of subjects: 120
Study 31551222 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose ambroxol
Number of subjects: 180
Study 31551222 — intervention group
Group type: COMPARATOR
Intervention: Small-dose ambroxol (Control)
Number of subjects: 180
Study 28620884 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Number of subjects: 0
Study 28620884 — intervention group
Group type: EXPERIMENTAL
Intervention: Nab-Paclitaxel
Number of subjects: 0
Study 28620884 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixabepilone
Number of subjects: 0
Study 28620884 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect response model with linear drug effect
Number of subjects: 0
Study 25666311 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (40 IU)
Number of subjects: 16
Study 25666311 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 24969152 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented Standard Care (ASC; lower dose)
Number of subjects: 202
Study 24969152 — intervention group
Group type: EXPERIMENTAL
Intervention: Resource Nurse Care (RNC; medium dose)
Number of subjects: 202
Study 24969152 — intervention group
Group type: EXPERIMENTAL
Intervention: Transitional Care Model (TCM; higher dose)
Number of subjects: 202
Study 24969152 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Status
Number of subjects: 202
Study 22713245 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucocorticoids (GCs)
Number of subjects: 300000000
Study 18066659 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-guided reading plus nicotine patch (n = 18)
Number of subjects: 40
Study 18066659 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing plus nicotine patch (n = 22)
Number of subjects: 40
Study 18066659 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 40
Study 18066659 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch compliance
Number of subjects: 40
Study 17870206 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Negotiated Interview (intervention group)
Number of subjects: 1132
Study 17870206 — intervention group
Group type: COMPARATOR
Intervention: Control group (written handout)
Number of subjects: 1132
Study 15168925 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.06 mg x Kg(‐1) of rocuronium
Number of subjects: 60
Study 15168925 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline solution
Number of subjects: 60
Study 12217089 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet training
Number of subjects: 100
Study 12217089 — intervention group
Group type: COMPARATOR
Intervention: Wait list control group
Number of subjects: 100
Study 9613753 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin injections (25-50 U per site, mean total dose 210 U, range 150-300 U)
Number of subjects: 5
Study 9613753 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin injections
Number of subjects: 5
Study 7851518 — intervention group
Group type: EXPERIMENTAL
Intervention: Split-belt locomotion with varying belt speeds (0.5, 1.0, 1.5, 2.0 m/s)
Number of subjects: 0
Study 7851518 — intervention group
Group type: EXPERIMENTAL
Intervention: Split-belt locomotion with faster ipsilateral belt speed
Number of subjects: 0
Study 7851518 — intervention group
Group type: EXPERIMENTAL
Intervention: Split-belt locomotion with slower contralateral belt speed
Number of subjects: 0
Study 7851518 — intervention group
Group type: EXPERIMENTAL
Intervention: Support phase on the faster side
Number of subjects: 0
Study 7851518 — intervention group
Group type: EXPERIMENTAL
Intervention: Support phase on the slower side
Number of subjects: 0
Study 2680315 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose therapy with sulfamethizole
Number of subjects: 41
Study 2680315 — intervention group
Group type: COMPARATOR
Intervention: Conventional six-day therapy with sulfamethizole
Number of subjects: 41
Study 31669050 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (D group) - loading dose of 0.5 μg/kg for 10 min, maintained at 0.5 μg/kg/h until liver resection
Number of subjects: 58
Study 31669050 — intervention group
Group type: COMPARATOR
Intervention: Control (C group) - 0.9% sodium chloride administered in the same volume and infusion rate as D group
Number of subjects: 58
Study 31669050 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (D group)
Number of subjects: 58
Study 31669050 — intervention group
Group type: COMPARATOR
Intervention: Control (C group)
Number of subjects: 58
Study 30883366 — intervention group
Group type: EXPERIMENTAL
Intervention: Oro-and naso-pharyngeal suction (ONPS)
Number of subjects: 84
Study 30883366 — intervention group
Group type: COMPARATOR
Intervention: No oro-and naso-pharyngeal suction (No-ONPS)
Number of subjects: 84
Study 28857498 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher self‐regulatory efficacy (SRE‐flare) individuals
Number of subjects: 0
Study 25894719 — intervention group
Group type: EXPERIMENTAL
Intervention: On-body injector
Number of subjects: 253
Study 25894719 — intervention group
Group type: COMPARATOR
Intervention: Manual injection
Number of subjects: 253
Study 23857075 — intervention group
Group type: EXPERIMENTAL
Intervention: Music (recordings selected by a music therapist via ambient speakers)
Number of subjects: 42
Study 23857075 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 42
Study 21067717 — intervention group
Group type: EXPERIMENTAL
Intervention: rFSH + rLH administration
Number of subjects: 720
Study 21067717 — intervention group
Group type: COMPARATOR
Intervention: rFSH administration
Number of subjects: 720
Study 19085014 — intervention group
Group type: EXPERIMENTAL
Intervention: EPO treatment
Number of subjects: 10
Study 19085014 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 10
Study 18181381 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil infusion (RI)
Number of subjects: 40
Study 18181381 — intervention group
Group type: COMPARATOR
Intervention: Remifentanil infusion with paracervical block (RI + PCB)
Number of subjects: 40
Study 14985684 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactulose (5 g b.i.d. for 6 weeks)
Number of subjects: 16
Study 14985684 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sucrose, 5 g b.i.d. for 6 weeks)
Number of subjects: 16
Study 11449021 — intervention group
Group type: EXPERIMENTAL
Intervention: Home based muscle strengthening and balance retraining programme
Number of subjects: 233
Study 11449021 — intervention group
Group type: COMPARATOR
Intervention: Usual care and social visits (control group)
Number of subjects: 233
Study 9926154 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing Problems Questionnaire (BPQ)
Number of subjects: 96
Study 9926154 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic Respiratory Disease Questionnaire (CRQ)
Number of subjects: 96
Study 9926154 — intervention group
Group type: EXPERIMENTAL
Intervention: Nottingham Extended ADL (NEADL)
Number of subjects: 96
Study 9926154 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Assessment of Depression Cards (BASDEC)
Number of subjects: 96
Study 9926154 — intervention group
Group type: EXPERIMENTAL
Intervention: 6‐min walk distance
Number of subjects: 96
Study 9926154 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass index
Number of subjects: 96
Study 9926154 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting oxygen saturation
Number of subjects: 96
Study 9926154 — intervention group
Group type: EXPERIMENTAL
Intervention: Household composition
Number of subjects: 96
Study 8089468 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple drug regimen including a macrolide for treatment of DMAC
Number of subjects: 0
Study 8089468 — intervention group
Group type: COMPARATOR
Intervention: Prophylaxis for patients with CD4 < 100 mm3
Number of subjects: 0
Study 3185621 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient cardiac catheterization
Number of subjects: 381
Study 3185621 — intervention group
Group type: COMPARATOR
Intervention: Inpatient cardiac catheterization
Number of subjects: 381
Study 30673688 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting
Number of subjects: 46
Study 30673688 — intervention group
Group type: EXPERIMENTAL
Intervention: Lying
Number of subjects: 46
Study 28481431 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive dissonance-based (DB) intervention
Number of subjects: 112
Study 28481431 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control condition
Number of subjects: 112
Study 26025259 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted implementation strategy for the Dutch multidisciplinary guideline for nonspecific low back pain
Number of subjects: 0
Study 26025259 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimedia intervention aimed at improving beliefs, cognitions, and self-management
Number of subjects: 0
Study 26025259 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted implementation strategy
Number of subjects: 0
Study 26025259 — intervention group
Group type: COMPARATOR
Intervention: Passive guideline dissemination
Number of subjects: 0
Study 24111816 — intervention group
Group type: EXPERIMENTAL
Intervention: Diluted bleach baths (soaked for 10 min, twice a week for 2 months)
Number of subjects: 0
Study 24111816 — intervention group
Group type: COMPARATOR
Intervention: Distilled water baths (placebo control)
Number of subjects: 0
Study 21726992 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated coffee
Number of subjects: 16
Study 21726992 — intervention group
Group type: COMPARATOR
Intervention: Decaffeinated coffee
Number of subjects: 16
Study 17698067 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonoscopy after screening colonoscopy in patients with neoplasia
Number of subjects: 3121
Study 17698067 — intervention group
Group type: COMPARATOR
Intervention: Colonoscopy after screening colonoscopy in neoplasia-free controls
Number of subjects: 3121
Study 17698067 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with 1 or 2 tubular adenomas <10 mm
Number of subjects: 3121
Study 17698067 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with 3 or more tubular adenomas <10 mm
Number of subjects: 3121
Study 17698067 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with tubular adenoma ≥10 mm
Number of subjects: 3121
Study 17698067 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with villous adenoma
Number of subjects: 3121
Study 17698067 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with adenoma with high-grade dysplasia
Number of subjects: 3121
Study 16137274 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise therapy
Number of subjects: 584
Study 11893345 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (10-80 mg/d)
Number of subjects: 60
Study 11893345 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 10459082 — intervention group
Group type: EXPERIMENTAL
Intervention: Long‐chain Triglycerides (LCTs)
Number of subjects: 76
Study 10459082 — intervention group
Group type: COMPARATOR
Intervention: Medium‐chain Triglycerides (MCTs)
Number of subjects: 76
Study 7842196 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (NO) at 10 ppm
Number of subjects: 35
Study 7842196 — intervention group
Group type: COMPARATOR
Intervention: Prostacyclin (PGI2)
Number of subjects: 35
Study 2104988 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose TRH (0.5 mg/kg) administered intravenously (IV)
Number of subjects: 0
Study 2104988 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered intravenously (IV)
Number of subjects: 0
Study 335498 — intervention group
Group type: EXPERIMENTAL
Intervention: 100-400 mg spironolactone
Number of subjects: 40